Wednesday, July 8, 2026

Patent intelligence · US

US 9265734

Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors

granted A61KA61K31/00A61K31/16A61P
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 10
Applicant portfolio 175
Patent details — US 9265734
Jurisdiction
US
Status
granted
Grant date
Feb 23, 2016
Expiration
Feb 18, 2036
Claims
39
CPC classes
A61K, A61K31/00, A61K31/16, A61P
View on Google Patents ↗

Quick answer

US 9265734 (Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors) is held by BIOMARIN PHARMACEUTICAL INC.. Status: granted. Granted Feb 23, 2016. Expires Feb 18, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
39
CPC classes
A61K, A61K31/00, A61K31/16, A61P, A61P21/00, A61P25/00

More from BIOMARIN PHARMACEUTICAL INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12427171

    Krill oil composition enriched in LPC-DHA and LPC-EPA

    Aker BioMarine Human Ingredients AS · Expires Sep 25, 2045

    granted
  2. US 12331293

    Bispecific antisense oligonucleotides for dystrophin exon skipping

    BIOMARIN TECHNOLOGIES B.V. · Expires Jun 12, 2045

    granted
  3. US 12239692

    Adeno-associated virus factor VIII vectors

    BIOMARIN PHARMACEUTICAL INC. · Expires Feb 27, 2045

    granted
  4. US 12233106

    C-type natriuretic peptide variants to treat skeletal dysplasia in children

    BIOMARIN PHARMACEUTICAL INC. · Expires Feb 20, 2045

    granted
  5. US 12214015

    Use of c-type natriuretic peptide variants to treat osteoarthritis

    BIOMARIN PHARMACEUTICAL INC. · Expires Jan 30, 2045

    granted
  6. US 12194064

    Process of producing concentrated therapeutic phospholipid composition from krill extracts containing high level of free fatty acids

    Aker BioMarine Human Ingredients AS · Expires Jan 9, 2045

    granted
  7. US 12188058

    Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

    BIOMARIN PHARMACEUTICAL INC. · Expires Jan 2, 2045

    granted
  8. US 12076372

    Use of C-type natriuretic peptide variants to treat skeletal dysplasia

    BIOMARIN PHARMACEUTICAL INC. · Expires Aug 29, 2044

    granted

Frequently asked questions

What is US patent 9265734?

US 9265734 (Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors) is held by BIOMARIN PHARMACEUTICAL INC.. Status: granted. Granted Feb 23, 2016. Expires Feb 18, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9265734?

BIOMARIN PHARMACEUTICAL INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 175 pharmaceutical patents for this assignee.

When does US 9265734 expire?

Our index shows an expiration date of Feb 18, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.